Search Results
Your search for all items matches 34700 pages
Showing 12201 - 12250
Parameswaran Hari, MD, on Multiple Myeloma: Post-Autologous Hematopoietic Cell Transplantation Strategies in Upfront Treatment
Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses phase III data from a 6-year follow-up of the STaMINA trial, which compared progression-free survival among 758 patients with high-risk multiple myeloma who received a second autologous transplant and lenalidomide maintenance;...
Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract...
Expert Point of View: Scott N. Gettinger, MD
Discussant for the CheckMate 227 and CheckMate 9LA trials, Scott N. Gettinger, MD, of Yale Cancer Center in New Haven, Connecticut, said: “There is tremendous interest in lung cancer to combine nivolumab plus ipilimumab, driven by the melanoma experience. However, combinations of immunotherapy come ...
Survival Disparities Seen in Hispanic Patients With Blood Cancers Living Near the United States/Mexico Border
A study by Bencomo-Alvarez et al investigating the incidence and survival for Hispanic patients with hematologic malignancies living along the United States/Mexico border in El Paso, Texas, has found that those patients with acute myeloid leukemia, acute lymphoblastic leukemia, or chronic myeloid...
Positive Findings in NSCLC for First-Line Nivolumab Plus Ipilimumab With or Without Chemotherapy
It is becoming more challenging to select first-line therapy for advanced non–small cell lung cancer (NSCLC) for patients whose tumors have no EGFR or ALK alterations. The results of two different studies presented at the ASCO20 Virtual Scientific Program—CheckMate 227 and CheckMate 9LA—support the ...
Young Adults With Cancer May Benefit From Germline Genetic Testing
According to the National Cancer Institute, each year, about 70,000 adolescents and young adults (AYA)—those between the ages of 15 and 39—are diagnosed with cancer. Evidence suggests that some cancers found in AYA patients may have unique genetic and biologic features. A study that investigated...
Factors Associated With COVID-19 Infection Severity in Patients With Cancer: Wuhan City Study
In a retrospective cohort study reported in The Lancet Oncology, Tian et al identified factors associated with severity of illness in patients with cancer hospitalized for COVID-19 over a 2-month period in Wuhan. Study Details The study included all patients aged ≥ 18 years with any type of solid...
Salvage Nivolumab/Ipilimumab After Prior Immune Checkpoint Inhibitor Therapy in Patients With Metastatic Renal Cell Carcinoma
In a study reported in the Journal of Clinical Oncology, Gul et al found that salvage therapy with nivolumab/ipilimumab was capable of producing a response after prior programmed cell death 1 (PD-1) pathway inhibitor therapy in some patients with metastatic renal cell carcinoma. Study Details The...
Findings in Prostate Cancer From the ASCO20 Virtual Scientific Program
This week, we're hearing from the authors of three high-impact papers on research in prostate cancer presented during the ASCO20 Virtual Scientific Program.
Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable...
Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
SIR 2020 Virtual: Transarterial Chemoperfusion for Patients With Mesothelioma
A novel treatment for patients with advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology (SIR) 2020 Annual...
SIR 2020 Virtual: Holographic Visualization for Ablation of Liver Tumors
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of...
Cisplatin/Fluorouracil vs Carboplatin/Paclitaxel in Chemotherapy-Naive Patients With Advanced Anal Cancer
In an International Rare Cancers Initiative phase II trial (InterAAct) reported in the Journal of Clinical Oncology, Rao et al found that carboplatin/paclitaxel was associated with less serious toxicity and a trend toward improved overall survival vs cisplatin/fluorouracil in chemotherapy-naive...
First-Line Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for SCLC Brain Metastases
In a cohort analysis reported in JAMA Oncology, Rusthoven et al found that first-line stereotactic radiosurgery was associated with similar outcomes as whole-brain radiotherapy in patients with small cell lung cancer (SCLC) brain metastases. As stated by the investigators, “Although stereotactic...
Impact of Medicare OCM Reporting Requirements on Biomarker Testing and Treatment in Advanced NSCLC
In a study reported in JCO Oncology Practice, Emily H. Castellanos, MD, MPH, and colleagues found that the requirement for Medicare Oncology Care Model (OCM) practices to report biomarker testing of patients with advanced non–small cell lung cancer (NSCLC) has not substantially altered the...
Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provide durable and long-term overall survival benefit vs platinum-doublet chemotherapy as first-line treatment for patients with...
Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).
FDA Grants Accelerated Approval to Tazemetostat for Some Patients With Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have...
Percutaneous Cryoablation vs Partial or Radical Nephrectomy for Early-Stage Kidney Cancer
A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by...
UKCCMP Prospective Cohort Study of COVID-19 Mortality in Patients With Cancer
As reported by Lee et al in The Lancet, a prospective cohort study from the United Kingdom performed by the UK Coronavirus Cancer Monitoring Project (UKCCMP) has found that increased risk of COVID-19 mortality in patients with cancer is associated with such factors as age, sex, and comorbidities,...
Role of Genetic Mutations and Treatment Exposures in Increased Subsequent Malignancy Risk for Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Qin et al identified combinations of pathogenic germline mutations in DNA repair genes and cancer treatment exposures that increased risk of subsequent neoplasms in long-term survivors of childhood cancer. Study Details The study involved...
Tafasitamab Plus Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In the phase II L-MIND trial reported in The Lancet Oncology, Gilles Salles, MD, and colleagues found that the combination of the Fc-enhanced anti-CD19 monoclonal antibody tafasitamab plus lenalidomide produced responses in patients with relapsed or refractory diffuse large B-cell lymphoma...
Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a...
Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT
Christopher Nutting, MD, PhD, of the Royal Marsden Hospital and Institute of Cancer Research, discusses phase III results from the first study to demonstrate the functional benefit of swallow-sparing intensity-modulated radiotherapy in oro- and hypopharyngeal cancers (Abstract 6508).
Immunogenomic Characteristics of Advanced Clear Cell Kidney Cancer Treated With Checkpoint Inhibitors
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitors. The research was presented during the ASCO20 Virtual Scientific...
Ripretinib in Previously Treated Patients With Advanced GIST: INVICTUS Trial
As reported in The Lancet Oncology by Jean-Yves Blay, MD, and colleagues, the phase III INVICTUS trial has shown that the oral KIT and PDGFRα tyrosine kinase inhibitor ripretinib prolonged progression-free survival vs placebo in patients with advanced gastrointestinal stromal tumors (GIST) whose...
HLA-DP Expression and Risk of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation
In a study reported in the Journal of Clinical Oncology, Petersdorf et al found that level of expression of patient HLA-DPB1 mismatches and number of mismatches affect risk of acute graft-vs-host disease (GVHD) after unrelated donor hematopoietic cell transplantation. Study Details The study...
American Cancer Society Updates Guideline for Diet and Physical Activity
The American Cancer Society has updated its guideline on diet and physical activity for cancer prevention. Staying at a healthy weight, staying active throughout life, following a healthy eating pattern, and avoiding or limiting alcohol may greatly reduce a person's lifetime risk of developing or...
FDA Approves Pembrolizumab for Adults and Children With Tumor Mutational Burden–High Solid Tumors
On June 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high (TMB-H; ≥ 10 mutations/megabase [mut/Mb]) solid tumors, as determined by an ...
Douglas B. Johnson, MD, on Melanoma: Clinical Trials Update on PD-1 and CTLA-4 Blockade
Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab in combination immunotherapy; antitumor activity for low-dose ipilimumab with pembrolizumab after disease progression on PD-1...
Jeremy L. Warner, MD, on the Clinical Impact of COVID-19 on Patients With Cancer
Jeremy L. Warner, MD, of Vanderbilt-Ingram Cancer Center, discusses data from the COVID-19 and Cancer Consortium cohort study, which included patients with active or prior hematologic or invasive solid malignancies, reported across academic and community sites (Abstract LBA110).
Retrospective Study of Characteristics and Outcomes in Patients With Cancer Hospitalized With COVID-19 in Hubei
In a retrospective cohort study reported in The Lancet Oncology, Yang et al described clinical characteristics, outcomes, and risk factors for mortality in patients with cancer hospitalized with COVID-19 over a 2-month period in Hubei, China. Study Details The study included 205 patients with...
Stereotactic Ablative Radiotherapy for Oligometastatic Cancer: Long-Term Findings From the SABR-COMET Trial
In a long-term follow-up of the phase II SABR-COMET trial reported in the Journal of Clinical Oncology, David A. Palma, MD, PhD, and colleagues found that the addition of stereotactic ablative radiotherapy (SABR) to palliative standard-of-care treatment in patients with oligometastatic cancers...
First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer
In the phase II portion of a single-center phase I/II trial reported in JAMA Oncology, Yu et al found that the combination of first-line osimertinib and bevacizumab resulted in a high rate of 1-year progression-free survival in patients with metastatic EGFR-mutant lung cancer. As stated by the...
Effect of Functional Impairment on Hospitalized Patients With Cancer
New research published by Lage et al in JNCCN–Journal of the National Comprehensive Cancer Network found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission—meaning they needed assistance with activities of daily living like walking,...
FDA Extends Indication of Gemtuzumab Ozogamicin for Pediatric Patients With CD33-Positive AML
On June 16, the U.S. Food and Drug Administration (FDA) extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients aged 1 month and older. AAML0531 Efficacy and safety in the pediatric population were...
FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC
On June 15, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin (Zepzelca) for adult patients with metastatic small cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy. PM1183-B-005-14 Trial Efficacy was demonstrated in the...
Early Data Suggest Activity for Oral Selective Estrogen Receptor Degrader in Combination Regimen
The availability of an oral selective estrogen receptor degrader (SERD) would be good news for patients and clinicians as an alternative to intramuscular fulvestrant. The novel agent LSZ102 might fit the bill, based on early activity shown in combination with the targeted agents ribociclib and...
EHA25 Virtual: Roundup of Findings in Leukemia, Lymphoma, and More
Advances in the treatment of hematologic malignancies and some of their associated symptoms were presented during EHA25 Virtual, an ongoing online conference from the European Hematology Association (EHA). Advances in the Treatment of High-Risk CLL: CLL2-GIVe Results In the CLL2-GIVe trial, the...
FDA Approves Nine-Valent HPV Vaccine for the Prevention of Certain HPV-Related Head and Neck Cancers
On June 12, Merck announced that the U.S. Food and Drug Administration (FDA) had approved an expanded indication for Gardasil 9—a human papillomavirus (HPV) nine-valent vaccine—for the prevention of oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58....
Immune Checkpoint Inhibitor Rechallenge in Metastatic Renal Cell Carcinoma
In a study presented at the ASCO20 Virtual Scientific Program (Abstract 5077) and published as a brief report in JAMA Oncology, Ravi et al found that rechallenge with immune checkpoint inhibitor therapy was capable of producing responses in patients with metastatic renal cell carcinoma, including...
FGFR1–3 Inhibitor AZD4547 in Refractory Tumors Harboring FGFR Activating Mutations and Fusions
As reported in the Journal of Clinical Oncology by Chae et al, findings in a cohort of the phase II NCI-MATCH trial (EAY131, Subprotocol W) indicated that the oral inhibitor of fibroblast growth factor receptor 1, 2, and 3 (FGFR1–3), AZD4547, produced a small number of responses in patients with a...
Acalabrutinib vs Idelalisib/Rituximab or Bendamustine/Rituximab for Relapsed or Refractory CLL: ASCEND Trial
As reported in the Journal of Clinical Oncology by Ghia et al, the phase III ASCEND trial has shown prolonged progression-free survival with acalabrutinib monotherapy vs investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in adult patients with relapsed or refractory...
Plenary Research From the ASCO20 Virtual Scientific Program: Part 2
This week, we’ll review two late-breaking abstracts from the ASCO20 Virtual Scientific Program that reported negative results. Both were presented during the plenary program.
Expert Point of View: Julia R. White, MD
Julia R. White, MD, Professor of Radiation Oncology at The Ohio State University, Columbus, and the invited discussant of E2108, put these findings into context with three important studies evaluating the benefit of locoregional therapy for de novo stage IV breast cancer: the study from Tata...
Study Finds No Survival Benefit From Local Therapy for de Novo Metastatic Breast Cancer
Women presenting with newly diagnosed de novo metastatic breast cancer derived no additional survival benefit from surgery and radiotherapy given after systemic treatment, although the practice may reduce locoregional progression of disease, according to the results of the phase III E2108 study...
Factors Associated With All-Cause 30-Day Mortality in Patients With Cancer Infected With COVID-19: CCC19 Database Analysis
As reported in The Lancet by Jeremy L. Warner, MD, and colleagues, a cohort study using the COVID-19 and Cancer Consortium (CCC19) database has shown that increased risk of all-cause mortality in patients with cancer infected with COVID-19 is associated with such factors as increased age, male sex, ...
Addition of Pemetrexed vs Vinorelbine to Adjuvant Cisplatin for Nonsquamous NSCLC
In the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant therapy with pemetrexed/cisplatin did not result in superior recurrence-free survival but was better tolerated than vinorelbine/cisplatin in patients with completely resected...
